~/blog/tga-nad-nadh-listed-medicine-naming
Australia draws a line at the name: NAD, NAD+ and NADH off the front of the tub
Guidance published on 12 August treats NAD, NAD+ and NADH as unapproved ingredients for listed medicines, which makes them a problem in a product name before anyone argues about the claim underneath.
Read the front of a tub and you learn what a brand wants you to believe is inside it. Australia’s medicines regulator has decided that, for one small family of molecules, the name was doing more work than the formula behind it.
NutraIngredients reported on 26 August that the Therapeutic Goods Administration issued guidance on 12 August covering how NAD, NAD+, NADH and NMN may be represented in listed medicines. Of those four, the report says, only nicotinamide mononucleotide — NMN — counts as an approved ingredient for complementary medicines there. The other three do not, and per that report cannot headline a product name.
The examples are the useful part
The names the guidance treats as unacceptable, per that report, are ordinary shelf names rather than exotic ones: “NAD”, “Bean’s NADH Supplement”, “NAD+ 50”, “NAD Booster” and “NAD+ Enhance”. The stated reasoning, quoted in the report, is that names carrying these terms “may reasonably lead consumers to expect that the medicine either contains those ingredients” — or be read as indications for it. Note that the quoted passage names NMN too, and rests the objection on impermissible indications rather than on ingredient status alone.
That second half is the more interesting half. A name is not decoration. Put a molecule in it and you have made two assertions at once: that the substance is in there, and that having it in there is the point.
Why this lands on a nootropics shelf
NAD-adjacent products are rarely sold as cognitive supplements in so many words, but they are sold in the same aisle and the same vocabulary — cellular energy, mental clarity, the fog lifting by mid-morning. Naming sits upstream of every evidence argument this desk usually has. Before asking whether a dose was studied, in whom, and for how long, you have to establish that the named substance is actually in the bottle. A precursor is not the molecule it precedes, and “booster” is a verb doing a noun’s job.
What it does not do
It applies in Australia. A US or UK panel is untouched, and none of it settles whether any of these ingredients do anything worth paying for. The report describes no transition period and no relabelling deadline, but a slower mechanism: a listed product can stay on the Australian Register of Therapeutic Goods while its sponsor and the regulator work the question through, with cancellation held back as the final step if non-compliance is confirmed. Shelves change slowly under that arrangement, and unevenly.
Like the comment-stage rulemaking running elsewhere, a naming rule is a transparency mechanism, not a verdict on efficacy — it tells you nothing about whether a molecule works. These are supplements: the FDA has evaluated none of these statements, and none is offered as a way to diagnose, treat, cure or prevent a disease. If you already take something daily, the interaction question belongs with a clinician rather than with a product name.